{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:30:42Z","timestamp":1784863842009,"version":"3.55.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>As the second leading cause of death and disability worldwide, stroke is mainly caused by atherosclerosis and cardiac embolism, particularly in older individuals. Nevertheless, in young and otherwise healthy individuals, the causes of stroke can be more diverse and may include conditions such as patent foramen ovale, vasculitis, coagulopathies, genetic factors, or other undetermined causes. Although these other causes of stroke account for a relatively small proportion compared to ischemic stroke, they are becoming increasingly common in clinical practice and deserve attention. Here, we present a rare female patient with polycythemia vera (PV) who was admitted to the hospital as a stroke patient without any previous medical history.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 40-year-old young woman felt sudden dizziness and slow response. After 4 days of being admitted, she developed blurry vision on the right.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Cranial magnetic resonance imaging revealed aberrant signals in the left temporal and parietal lobe, as well as multiple small focal signal abnormalities were observed in the left frontal lobe. Magnetic resonance angiography revealed partial stenosis of the left internal carotid artery. The patient\u2019s blood routine examination revealed a significant elevation in complete blood counts, particularly the increase in red blood cells, as well as prolonged clotting time. An abdominal ultrasound and abdomen computed tomography showed splenomegaly. The outcome of the genetic testing was positive for the Janus kinase JAK2 exon V617F mutation (JAK2\/V617F). The patient was diagnosed with PV-related stroke.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with phlebotomy, cytoreductive therapy, and low-dose aspirin antiplatelet therapy and was regularly followed up in hematology and neurology clinics after discharge.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient\u2019s red blood cell, leukocyte, and thrombocyte counts had fully normalized, with her hemoglobin level measuring at 146\u2009g\/L and hematocrit value at 43%. Furthermore, there had been a significant improvement in neurological symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>PV, a rare hematological disorder, can present with ischemic stroke as the initial performance, and the diagnosis mainly relies on routine blood tests, bone marrow biopsies, and genetic test. Therefore, clinicians should pay attention to PV, a low-prevalence disease, when encountering stroke in youth.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036953","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T19:06:09Z","timestamp":1708110369000},"page":"e36953","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review"],"prefix":"10.1097","volume":"103","author":[{"given":"Shuo","family":"Hui","sequence":"first","affiliation":[{"name":"Department of Graduate School, Hebei Medical University, Shijiazhuang, Hebei, China"},{"name":"Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2967-4060","authenticated-orcid":false,"given":"Jingru","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, China"},{"name":"Biology Post-doctoral Research Stations, Hebei Normal University, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, China"},{"name":"Biology Post-doctoral Research Stations, Hebei Normal University, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipeng","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, China"},{"name":"Biology Post-doctoral Research Stations, Hebei Normal University, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhao","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, China"},{"name":"Biology Post-doctoral Research Stations, Hebei Normal University, Shijiazhuang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei, China"},{"name":"Department of Graduate School, North China University of Science and Technology, Tangshan, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00019052-199502000-00007","article-title":"Hematologic disorders and ischemic stroke.","volume":"8","author":"Weksler","year":"1995","journal-title":"Curr Opin Neurol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1161\/01.STR.21.8.1111","article-title":"Hematologic disorders and ischemic stroke: a selective review.","volume":"21","author":"Hart","year":"1990","journal-title":"Stroke"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances.","volume":"30","author":"Barbui","year":"2016","journal-title":"Blood Rev"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1752-1947-7-131","article-title":"Acute embolic cerebral ischemia as an initial presentation of polycythemia vera: a case report.","volume":"7","author":"Zoraster","year":"2013","journal-title":"J Med Case Rep"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera.","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2013-06-501452","article-title":"JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.","volume":"122","author":"Hobbs","year":"2013","journal-title":"Blood"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms, and management.","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances.","volume":"30","author":"Barbui","year":"2016","journal-title":"Blood Rev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.08.040","article-title":"A case of recurrent ischemic stroke involving subacute, progressive intracranial cerebral arterial sclerosis prior to diagnosis with JAK2-mutated polycythemia vera.","volume":"24","author":"Nezu","year":"2015","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am J Hematol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera.","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.","volume":"33","author":"Falanga","year":"2005","journal-title":"Exp Hematol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases.","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases.","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera.","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:17:43Z","timestamp":1746328663000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036953","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}